.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
QuintilesIMS
Colorcon
Fuji
Harvard Business School
Julphar
AstraZeneca
Boehringer Ingelheim
Federal Trade Commission
McKinsey

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202155

« Back to Dashboard
NDA 202155 describes ELIQUIS, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ELIQUIS profile page.

The generic ingredient in ELIQUIS is apixaban. There are twenty-four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apixaban profile page.

Summary for NDA: 202155

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 202155

Mechanism of ActionFactor Xa Inhibitors

Suppliers and Packaging for NDA: 202155

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELIQUIS
apixaban
 TABLET;ORAL 202155 NDA E.R. Squibb & Sons, L.L.C. 0003-0893 0003-0893-21 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0003-0893-21)
ELIQUIS
apixaban
 TABLET;ORAL 202155 NDA E.R. Squibb & Sons, L.L.C. 0003-0893 0003-0893-31 10 BLISTER PACK in 1 CARTON (0003-0893-31) > 10 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG
Approval Date:Dec 28, 2012TE:RLD:Yes
Patent:9,326,945Patent Expiration:Feb 24, 2031Product Flag?YSubstance Flag?Delist Request?
Regulatory Exclusivity Expiration:Aug 21, 2017
Regulatory Exclusivity Use:INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Regulatory Exclusivity Expiration:Aug 21, 2017
Regulatory Exclusivity Use:INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Fish and Richardson
Farmers Insurance
Cipla
Queensland Health
Colorcon
QuintilesIMS
AstraZeneca
Julphar
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot